IQ Proteomics, LLC

Vedanta Biosciences, Inc., based in Cambridge, MA, is at the forefront of developing first-in-class Live Biotherapeutic Products (LBPs) to address serious gastrointestinal diseases through the strategic use of defined bacterial consortia. The company is focused on advancing innovative treatments for conditions such as inflammatory bowel disease and recurrent Clostridium difficile infections, with ongoing clinical trials to evaluate the efficacy and safety of its drug candidates. Committed to improving patient outcomes, Vedanta emphasizes the importance of gut health and the role of dysbiosis in gastrointestinal disorders. Through a robust scientific framework, the company leverages its expertise in immune response stimulation and microbial therapies to usher in a new era of gastrointestinal health management. Generated from the website

HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, MA. They are dedicated to revolutionizing the development of immunotherapies by utilizing their unique high-resolution translational platform, DIS, which provides an unprecedented understanding of immune dysregulation at the single cell level. Their goal is to enhance the probability of success for immunotherapies and improve patient outcomes through single-cell precision. With a focus on single cell science, HiFiBiO Therapeutics applies this approach at every stage of drug development, from target discovery to predictive biomarkers. This enables them to rapidly advance new therapeutics into the clinic, ultimately aiming to unlock the curative powers of the immune system. Through strategic collaborations and groundbreaking initiatives, they are at the forefront of personalized immunotherapies and have been recognized for their innovative Drug Intelligence Science (DIS) platform.Generated from the website

Vaxess Technologies, based in Cambridge, MA, is dedicated to transforming access to vaccines and therapeutics through innovative biomedical solutions. Their team of diverse life scientists, engineers, and entrepreneurs is committed to developing groundbreaking technologies that improve human health worldwide. Utilizing the skin as a delivery pathway, Vaxess' mimix patch delivers bioactive compounds to the body, offering a unique approach to vaccine and therapeutic delivery. By combining immune activating biology with adaptive silk biomaterials, Vaxess is pioneering vaccines and therapeutics that stand out from existing technologies. Generated from the website